Solvonis Therapeutics' chief scientific officer, Professor David Nutt, will speak at the 14th Joint Meeting of US federal addiction research bodies on May 6, 2026. He is the sole external speaker at this NIH-coordinated event, discussing psychedelic therapy for addictions, which aligns with Solvonis' drug development programs for alcohol and stimulant use disorders. This highlights the company's relevance in cutting-edge addiction treatment research, although it does not imply official endorsement by US agencies.
Citizens Community Bancorp, Inc. reported a Q2 earnings per share (EPS) of $0.11, significantly missing analyst expectations of $0.41, marking a 73.17% earnings surprise. The company's revenue also fell short at $16.11 million, slightly down from las...
Rambus Inc. is poised for growth in the AI memory market as it prepares to release its quarterly earnings report. Analysts expect an EPS of $0.72 and revenue around $199.3 million, up from $180.19 million last quarter, driven by increased demand for ...
Alliance Resource Partners reported Q2 revenue of $551.6 million, slightly below estimates, due to lower coal prices despite higher sales volumes. The company saw a 33.9% rise in net income to $79.6 million, supported by strong oil and gas royalties....
Welltower is set to report strong Q2 revenue growth of about $3.43 billion, a 34.5% increase year-over-year, reflecting robust demand in healthcare real estate. Earnings per share estimates vary widely, from $0.64 to $1.55, indicating uncertainty in ...
Christian Dior reported strong first-half 2026 results with €38.6 billion in sales and an operating profit of €8.7 billion, maintaining a high operating margin of 22.5%. The group saw a 3% organic sales growth in Q2, driven by strong performances in ...
